FDA Drug Regulation & Scheduling
Material regulatory developments from U.S. Food and Drug Administration and U.S. Drug Enforcement Administration are tracked daily by Cresthaven Analytics. Over the last 90 days, 1 material brief relevant to professionals operating in the healthcare & life sciences sector have been published below. Each brief is sourced directly from the primary regulatory feed, summarized for institutional readers, and scored for materiality.
Recent material activity
-
FDA issues Complete Response Letter for novel GLP-1 receptor agonist oral formulation
The FDA issued a CRL for a once-daily oral GLP-1 receptor agonist citing manufacturing consistency concerns at the primary production facility. The agency requested additional CMC data and a pre-approval inspection befor…
Read a full sample brief →
Get every FDA Drug Regulation & Scheduling brief delivered the day it lands
From $149/month
Cresthaven Analytics monitors U.S. Food and Drug Administration and U.S. Drug Enforcement Administration continuously, applying institutional materiality scoring to every release. Subscribers receive structured briefs via email, portal, and (Executive tier and above) real-time alerts.
View all tiers →